EMFIZATAMAB

UNII:	FB8PCJ9N3H
Formula:
Preferred Substance Name:	EMFIZATAMAB
GSRS Full Record:	FB8PCJ9N3H i

2559704-23-1
EMFIZATAMAB [INN]
EMFIZATAMAB [WHO-DD]
IMMUNOGLOBULIN, ANTI-(HUMAN CD3 ANTIGEN .EPSILON.-CHAIN) (HUMAN-ORYCTOLAGUS CUNICULUS CLONE 284A10 SINGLE-CHAIN VARIABLE FRAGMENT VL-(GGGGS)4-VH) FUSION PROTEIN WITH PEPTIDE LINKER (GGGGS)2 FUSION PROTEIN WITH IMMUNOGLOBULIN G1 ANTI-(HUMAN CD19 ANTIGEN) (DE-713-LYSINE) (HUMAN CLONE 21D4 .GAMMA.1-CHAIN) FUSION PROTEIN WITH PEPTIDE LINKER (GGGGS)2 FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN PROGRAMMED DEATH-LIGAND 1) (HUMAN-ORYCTOLAGUS CUNICULUS CLONE PL221G5 SINGLE-CHAIN VARIABLE FRAGMENT VH-(GGGGS)4-VL) FUSION PROTEIN WITH PEPTIDE LINKER (GGGGS)2 FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN 4-1BB RECEPTOR) (HUMAN-ORYCTOLAGUS CUNICULUS CLONE 466F6 SINGLE-CHAIN VARIABLE FRAGMENT VH-(GGGGS)4-VL), DISULFIDE WITH HUMAN CLONE 21D4 .KAPPA.-CHAIN, DIMER

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

EMFIZATAMAB

Synonyms and Mappings

Resources